Glofitamab for high-risk large B-cell lymphoma after first treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called glofitamab (a type of immunotherapy) given as a follow-up treatment after initial therapy for people with high-risk large B-cell lymphoma. The goal is to see if it helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of large B-cell lymphoma (like DLBCL) that is considered high-risk (for example, with certain genetic changes or a large tumor).
- Your cancer responded well to your first treatment (you achieved complete remission or very good partial remission).
- You have not had certain other treatments like CAR-T therapy or a stem cell transplant recently, and do not have active hepatitis B or C.
- You agree to use effective birth control if you or your partner could become pregnant, lasting for at least 2 years after treatment.
- Your overall health is good enough for the trial, with normal organ function (heart, lungs, liver, kidneys) and no serious infections or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well the drug glofitamab works in people whose diffuse large B-cell lymphoma (a common type of lymphoma) didn't respond to, or came back quickly after, their first therapy. The goal is to learn how effective and safe glofitamab is in the real world when it is added to standard care.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial tests a drug called glofitamab, which helps your immune system attack lymphoma cells. It is for people with aggressive B-cell lymphoma that has grown after standard treatments. The study uses a biopsy to tailor the treatment during therapy.
This trial tests combining two therapies—a CAR T-cell treatment and an antibody drug called glofitamab—for people with large B-cell lymphoma that has come back or not responded to initial treatment and has certain high-risk features.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
Hear when a new B Cell Lymphoma (BCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.